Currently, Phase III clinical trials are in progress aimed at assessing the use of several PARP inhibitors (e.g. Olaparib, Niraparib, Recuparib, Veliparib, and BMN-673) in the maintenance therapy of platinum treated ovarian and breast cancer, as single agents in therapeutic settings of adjuvant and standard-of-care chemotherapy for advanced diseases. Here, PARP1 is linked to breast cancer.